4 Results for "

KRAS Q61H mutant cancers

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "KRAS Q61H mutant cancers" in MCE Product Catalog:

Cat. No.: HY-156529
CAS No.: 2882825-14-9
Purity:  98.01%
Target:  

Ras

Research Areas:  

Cancer

pan-KRAS-IN-2 (Compound 6) is a pan-inhibitor with IC50s ≤ 10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A and Q61H); and an IC50 > 10 μM for KRAS G13D. pan-KRAS-IN-2 can be used to study various KRAS-mediated cancers, such as pancreatic cancer and colorectal cancer .
loading...
    loading...
Cat. No.: HY-P2265A
CAS No.: 2896737-31-6
Target:  

SOS1 Ras

Research Areas:  

Cancer

SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .
loading...
    loading...
Cat. No.: HY-P2265
CAS No.: 1652561-87-9
Target:  

SOS1 Ras

Research Areas:  

Cancer

SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .
loading...
    loading...
Cat. No.: HY-186087
CAS No.: 3058972-05-4
Target:  

Ras ERK Cyclophilin

Research Areas:  

Cancer

RM-046 is an orally active, selective ternary complex inhibitor of KRAS Q61H (active form). RM-046 forms a ternary complex with cyclophilin A, binds to active KRAS Q61H in a non-covalent manner, blocks effector binding via steric hindrance and inhibits downstream signal transduction. RM-046 inhibits ERK phosphorylation and cancer cell proliferation, and induces sustained RAS pathway signal inhibition, anti-tumor activity and tumor regression in preclinical xenograft models. RM-046 can be used for the research of KRAS Q61H mutant cancers .
loading...
    loading...